How does the WHI study alter the risk - Benefit ratio of HT?

Fertility and Sterility

Volumn 80, Issue SUPPL. 4, 2003, Pages 19-26

  Collins, John A ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CARCINOMA; CANCER CYTODIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CLINICAL RESEARCH; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FOLLOW UP; HAZARD ASSESSMENT; HEART PROTECTION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 14344255365     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)01148-8     Document Type: Review

References (19)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 288:2002;321-333
2. Pignone M., Phillips C., Mulrow C.D. Use of lipid lowering drugs for primary prevention of coronary heart disease meta-analysis of randomised trials. BMJ. 321:2000;983-986
3. Guyatt G.H., Rennie D. Users' guides to the medical literature. JAMA. 270:1993;2096-2097
4. The Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature A Manual for Evidence-Based Clinical Practice. 2002;AMA Press, Chicago
5. Sackett D.L., Rosenberg W.M.C., Gray J.A.M., Haynes R.B., Richardson W.S. Evidence-based medicine what it is and what it isn't. BMJ. 312:1996;56-57
6. Freedman L., Anderson G., Kipnis V., Prentice R., Wang C.Y., Rossouw J., et al. Approaches to monitoring the results of long-term disease prevention trials examples from the Women's Health Initiative. Controlled Clin Trials. 17:1996;509-525
7. The ESHRE Capri Workshop Group. Continuation rates for oral contraceptives and hormone replacement therapy. Hum Reprod. 15:2000;1865-1871
8. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54
9. Speroff L., Symons J., Kempfert N., Rowan J. femhrt Study Investigators. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause. 7:2000;383-390
10. Brewer D., Nashelsky J., Hansen L.B. What nonhormonal therapies are effective for postmenopausal vasomotor symptoms? J Fam Pract. 52:2003;324-327
11. Kronenberg F., Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms a review of randomized, controlled trials. Ann Intern Med. 137:2002;805-813
12. Davis S.R., Briganti E.M., Chen R.Q., Dalais F.S., Bailey M., Burger H.G. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. A randomised controlled trial. Med J Aust. 174:2001;68-71
13. Clayden J., Bell J., Pollard P. Menopausal flushing double-blind trial of a non-hormonal medication. BMJ. 1:1974;409-412
14. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., Lavasseur B.I., Barton D.L., et al. Venlafaxine in management of hot flashes in survivors of breast cancer a randomised controlled trial. Lancet. 356:2000;2059-2063
15. Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 20:2002;1578-1583
16. Farley T.M.M., Collins J.A., Schlesselman J.J. Hormonal contraception and risk of cardiovascular disease an international perspective. Contraception. 57:1998;211-230
17. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528. VIGOR Study Group
18. Greendale G.A., Reboussin B.A., Sie A., Singh H.R., Olson L.K., Gatewood O., et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 130:1999;262-269
19. Rutter C.M., Mandelson M.T., Laya M.B., Seger D.J., Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 285:2001;171-176